WebBiofourmis Singapore Pte. Ltd. Vision Exchange, #07-15, 2 Venture Drive: Singapore, SG 608526 Applicant Contact: Kuldeep Singh Rajput: Correspondent: Daniel & Daniel Consulting, LLC ... MD 20993 Ph. 1-888-INFO-FDA (1-888-463-6332) Contact FDA. For Government; For Press; Combination Products; Advisory Committees; Science & … WebBOSTON, July 29, 2024 /PRNewswire/-- Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced today its BiovitalsHF® solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). BiovitalsHF® is a software medical ...
Biofourmis Solutions for life sciences
WebThis FDA approval is the second market authorization for Biofourmis, having earned the agency's approval in May 2024 for its Biovitals™ RhythmAnalytics™ platform, which is cloud-based software for automated interpretation of more than 15 types of cardiac arrhythmias. The newly cleared Analytics Engine is a much broader approval to process ... WebApr 26, 2024 · Coming nearly two years after the company's $100 million Series C, Biofourmis tallied its total raise at $445 million. AI-backed remote monitoring and digital therapeutics company Biofourmis raised a whopping $300 million in Series D funding, boosting the company to unicorn status with a valuation of $1.3 billion. hight4of5
Biofourmis reaches unicorn status with $300M Series D
WebApr 26, 2024 · biofourmis B iofourmis, a startup developing digital therapeutics and artificial intelligence to remotely monitor patients, said its valuation hit $1.3 billion after … WebPowered by our FDA cleared analytics engine, our solution enables the timely delivery of the right care to the right patient by employing features such as: ... The developer, Biofourmis Singapore Pte. Ltd., indicated that the app’s privacy practices may include handling of data as described below. WebDec 9, 2024 · To assess the effectiveness of the Biofourmis cloud-based BiovitalsHF™ DTx to improve guideline-directed medical therapy (GDMT) adoption in subjects with heart failure with reduced ejection fraction (HFrEF) after 90 days of using platform. ... Studies a U.S. FDA-regulated Drug Product: No: Studies a U.S. FDA-regulated Device Product: Yes: hightable.io